<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>LightSciences.com</title>
	<atom:link href="http://www.lightsciences.com/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.lightsciences.com</link>
	<description></description>
	<lastBuildDate>Fri, 27 Jan 2012 09:12:14 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.1</generator>
		<item>
		<title>Light Sciences Corporation</title>
		<link>http://www.lightsciences.com/health-well-being/light-sciences-corporation/</link>
		<comments>http://www.lightsciences.com/health-well-being/light-sciences-corporation/#comments</comments>
		<pubDate>Wed, 11 Jan 2012 18:35:04 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Health & Well-Being]]></category>
		<category><![CDATA[Other Health]]></category>
		<category><![CDATA[Technology]]></category>

		<guid isPermaLink="false">http://www.lightsciences.com/?p=13</guid>
		<description><![CDATA[&#160; &#160; &#160; Light Sciences Corporation comprises two companies developing Light InfusionTechnology ™ (Litx ™) for treatment of significant unmet medical needs incardiovascular and eye disease. Light Sciences has also continued to seek new applications for Litx on other important disease targets. Litx ™ is a combination product consisting of a proprietary photoreactive agent (LS11) activated by proprietary non-coherent light infusion devices. The goal of Litx™ is less poorly formed blood vessels that support the development of abnormaltissues in the proliferative diseases. Targeting age-related macular degeneration and other diseases affecting the backof the eye. Targeting of atherosclerosis, including peripheral arterial disease and vulnerableplaque. Light Sciences New Technology Group (NTG) is a seed-stage R &#38; D organizationchartered to incubate innovation and technology in a wide range of [...]]]></description>
		<wfw:commentRss>http://www.lightsciences.com/health-well-being/light-sciences-corporation/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

